Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross ProceedsPRNewsWire • 11/02/24
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor ConferencePRNewsWire • 09/23/24
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsPRNewsWire • 08/22/24
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD PatientsPRNewsWire • 08/20/24
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register NowGlobeNewsWire • 08/20/24
Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADsPRNewsWire • 08/06/24
Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024PRNewsWire • 07/17/24
Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024PRNewsWire • 06/11/24
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsPRNewsWire • 06/03/24
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024PRNewsWire • 05/23/24
Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024PRNewsWire • 04/11/24
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsPRNewsWire • 04/09/24
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferencePRNewsWire • 02/26/24
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialPRNewsWire • 02/08/24
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsPRNewsWire • 01/31/24
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024PRNewsWire • 01/24/24
Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferencePRNewsWire • 01/04/24
Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetPRNewsWire • 12/19/23
Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationPRNewsWire • 12/12/23